0001104659-23-031786.txt : 20230313 0001104659-23-031786.hdr.sgml : 20230313 20230313162259 ACCESSION NUMBER: 0001104659-23-031786 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230309 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230313 DATE AS OF CHANGE: 20230313 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HOOKIPA Pharma Inc. CENTRAL INDEX KEY: 0001760542 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 815395687 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38869 FILM NUMBER: 23727608 BUSINESS ADDRESS: STREET 1: 430 EAST 29TH STREET STREET 2: 14TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 0114318906360 MAIL ADDRESS: STREET 1: 430 EAST 29TH STREET STREET 2: 14TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 8-K 1 tm239380d1_8k.htm FORM 8-K
0001760542 false 0001760542 2023-03-09 2023-03-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): March 9, 2023

 

HOOKIPA PHARMA INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38869   81-5395687

(State or other jurisdiction of

incorporation)

  

(Commission File Number)

  

(I.R.S. Employer

Identification No.)

 

350 Fifth Avenue, 72nd Floor

Suite 7240

  
New York, New York   10018
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: +43 1 890 63 60

 

Not Applicable

Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Common stock, $0.0001 par value per share HOOK The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company  x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  x

 

 

 

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On March 9, 2023, the Board of Directors (the “Board”) of HOOKIPA Pharma Inc. (the Company”) appointed Terry Coelho as a director of the Board, effective April 3, 2023. Ms. Coelho will serve as a Class III director, to serve until the Company’s annual meeting of stockholders in 2025. Ms. Coelho will also serve as a member of the Compensation Committee of the Board and the Audit Committee of the Board commencing on April 3, 2023.

 

Ms. Coelho most recently served as Executive Vice President, Chief Financial Officer and Chief Business Development Officer for CinCor Pharma, Inc from November 2021 through November 2022. Prior to that, Ms. Coelho served as Executive Vice President and Chief Financial Officer of BioDelivery Sciences International from January 2019 to November 2021. Prior to that Ms. Coelho served as Chief Financial Officer of Balchem Corporation from October 2017 to October 2018. Prior to her time at Balchem, Ms. Coelho served as interim Chief Operating Officer and Chief Financial Officer at Diversey, Inc. from September 2017 to October 2017. From October 2014 to October 2017, Ms. Coelho served at Sealed Air Corporation, most recently as Vice President & Global Commercial Excellence, Diversey Care. Ms. Coelho’s experience also includes over seven years at Novartis Pharmaceuticals from March 2007 until October 2014, most recently as Global Head of Oncology Development Finance. Prior to that, Ms. Coelho spent over 20 years at Mars, Incorporated. Ms. Coelho is a member of the Board of Directors of First Wave BioPharma (NASDAQ: FWBI). Ms. Coelho received her B.A. from The American University in Washington, D.C. and earned her M.B.A. from the Instituto Brasileiro de Mercado de Capitais in Rio de Janeiro, Brazil. The Board believes Ms. Coelho’s business, strategic and leadership experience as well as her knowledge of the biotechnology industry makes her qualified to serve on the Company’s Board.

 

Ms. Coelho will be compensated for her service as a non-employee director pursuant to the Company’s Non-Employee Director Compensation Policy (the “Policy”). As a non-employee director, Ms. Coelho is entitled to an initial option to purchase 19,200 shares of the Company’s common stock and is also entitled to receive an annual cash retainer of $40,000 and additional annual stock option awards, subject to her continued service on the Board. As a member of the Audit Committee and Compensation Committee of the Board, Ms. Coelho is also entitled to receive an annual cash retainer of $15,000 and $10,000, respectively, subject to her continued service on the Audit Committee and Compensation Committee. Ms. Coelho may elect to receive stock options in lieu of such annual cash retainers.

 

The Company will also enter into an indemnification agreement with Ms. Coelho in connection with her appointment to the Board, which will be in substantially the same form as that entered into with the other directors of the Company. There are no other arrangements or understandings between Ms. Coelho and any other persons pursuant to which she was selected as a director, and Ms. Coelho has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

 

Item 7.01 Regulation FD Disclosure

 

On March 13, 2023, the Company issued a press release announcing the appointment of Ms. Coelho to the Board. A copy of this press release is furnished as Exhibit 99.1 to this report on Form 8-K.

 

The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 9.01. Exhibits

 

(d) Exhibits
   
99.1   Press Release issued by the Company on March 13, 2023, furnished herewith.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: March 13, 2023   HOOKIPA Pharma, Inc.  
           
    By: /s/ Joern Aldag
      Joern Aldag
      Chief Executive Officer
(Principal Executive Officer)

 

 

 

 EX-99.1 2 tm239380d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors

 

New York, US and Vienna, Austria, March 13, 2023 - HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced today that Terry Coelho will join its Board of Directors, Audit Committee and Compensation Committee, effective April 3, 2023.

 

“Terry is an immensely valuable addition to our Board, given her experience in business strategy, broad financial transactions and business development, and we are thrilled to welcome her to the team,” said Joern Aldag, Chief Executive Officer at HOOKIPA. “Terry has worked with companies large and small and navigated fast-paced, complex business environments, including in the pharmaceutical sector. We will undoubtedly benefit from her insights and expertise, as we advance our pipeline of arenaviral therapeutic candidates both in and towards the clinic.”

 

Ms. Coelho has over 35 years of experience as a multinational leader and executive with broad business, strategic and leadership experience in general management and across all areas of finance at public and private companies in multiple sectors, including pharmaceuticals. She most recently served as Executive Vice President, Chief Financial Officer and Chief Business Development Officer for CinCor Pharma, Inc, through November 2022. Prior to that, Ms. Coelho served in executive leadership roles, including Executive Vice President and Chief Financial Officer at BioDelivery Sciences International, and Chief Financial Officer at Balchem Corporation and Diversey, Inc. Ms. Coelho’s experience includes over seven years at Novartis Pharmaceuticals, primarily with the Oncology division, where she held roles of increasing responsibility focused in business planning and leading global oncology development finance. She began her career at Mars, Inc.

 

Ms. Coelho is a Member of the Board of Directors at First Wave BioPharma (NASDAQ: FWBI). She graduated summa cum laude from The American University in Washington, D.C. and earned her masters of business administration from the Instituto Brasileiro de Mercado de Capitais (IBMEC) in Rio de Janeiro, Brazil. Ms. Coelho is a founding member of the CFO Leadership Council (Charlotte and Raleigh chapters) and has served on the advisory board for Northeastern University’s M.B.A. Finance Track and the University of North Carolina at Charlotte Women in Business.

 

“It’s an exciting time to join HOOKIPA, with its strong pipeline in oncology and infectious diseases, as well as its strategic collaborations with premier players in the pharmaceutical sector,” said Terry Coelho. “I look forward to sharing my experience and perspective as the company drives its clinical programs forward and we continue with the next phase of growth.”

 

 

 

 

About HOOKIPA

 

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, prostate cancers, and other undisclosed oncology programs. HOOKIPA is collaborating with Roche on an arenaviral immunotherapeutic for KRAS-mutated cancers. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.

 

Find out more about HOOKIPA online at www.hookipapharma.com.

 

For further information, please contact:

 

Media Investors
   
Instinctif Partners Matt Beck
hookipa@instinctif.com Executive Director – Investor Relations
+44 (0)20 7457 2020 matthew.beck@hookipapharma.com

 

Forward Looking Statements

 

Certain statements set forth in this press release constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by terms such as “believes,” “expects,” “plans,” “potential,” “would” or similar expressions and the negative of those terms. Such forward-looking statements involve substantial risks and uncertainties that could cause HOOKIPA’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including HOOKIPA’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, HOOKIPA’s ability to successfully establish, protect and defend its intellectual property, risks relating to business interruptions resulting from the coronavirus (COVID-19) disease outbreak or similar public health crises, the impact of COVID-19 on the enrollment of patients and timing of clinical results, and other matters that could affect the sufficiency of existing cash to fund operations. HOOKIPA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see HOOKIPA’s quarterly report on Form 10-Q for the quarter ended September 30, 2022, which is available on the Security and Exchange Commission’s website at www.sec.gov and HOOKIPA’s website at www.hookipapharma.com.

 

Investors and others should note that we announce material financial information to our investors using our investor relations website (https://ir.hookipapharma.com/), SEC filings, press releases, public conference calls and webcasts. We use these channels, as well as social media, to communicate with our members and the public about our company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on the U.S. social media channels listed on our investor relations website.

 

 

 

 EX-101.SCH 3 hook-20230309.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 hook-20230309_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 hook-20230309_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm239380d1_ex99-1img001.jpg GRAPHIC begin 644 tm239380d1_ex99-1img001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Mar. 09, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 09, 2023
Entity File Number 001-38869
Entity Registrant Name HOOKIPA PHARMA INC.
Entity Central Index Key 0001760542
Entity Tax Identification Number 81-5395687
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 350 Fifth Avenue, 72nd Floor
Entity Address, Address Line Two Suite 7240
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10018
City Area Code +43
Local Phone Number 1 890 63 60
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, $0.0001 par value per share
Trading Symbol HOOK
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
XML 8 tm239380d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001760542 2023-03-09 2023-03-09 iso4217:USD shares iso4217:USD shares 0001760542 false 8-K 2023-03-09 HOOKIPA PHARMA INC. DE 001-38869 81-5395687 350 Fifth Avenue, 72nd Floor Suite 7240 New York NY 10018 +43 1 890 63 60 false false false false Common stock, $0.0001 par value per share HOOK NASDAQ true true EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( -R";58'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #<@FU6[CJPK>T K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)OITW00^CVLN))07!!\1:2V=U@DX9DI-VW-XV[740?P&-F_GSS M#4RG@]1CQ.-'?@D)11I& !5F$ELKXS6NJ(BL9XQAN]XL-G' K,:, !'7I*T-8ML'Z9 M&$[ST,$5L, (HTO?!30KL53_Q)8.L'-R3G9-3=-43Z+D\@XMO#T]OI1U*^L3 M*:\Q_TI6TBG@AETFOXKM_>Z!];SAHFI$U8H=;R3G\E:\+ZX__*[";C1V;_^Q M\46P[^#77?1?4$L#!!0 ( -R";5:97)PC$ 8 )PG 3 >&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ MW()M5@!X0<^C! Q( !@ !X;"]W;W)K.>WT0M@"-+$E'TF&Y-]W M98A-4[.FN0C^VM>/5JO=E7L[J5[TAC%#7N-(Z+ZS,2:YKM5TL&$QU5L[GO-^X9FO-\9>J UZ"5VS.3.?DYF"LUJN$O*8"^(/SG;ZZ)C8H2RE?+$GD[#ON):(12PP5H+"SY:-6!19)>#X=A!U\G=:P^/C M=_6[;/ PF"75;"2C+SPTF[[3<4C(5C2-S+/#G1F,Y):I7LV E+U0"PYF-WLS_X39(U57Q.U>$-_UZ_\V MKP%!CN'G&'ZF5\RWW5X2OGO/5,?7!K0Q2B$5#%F\)*X/#S3N7#PA$(X=HH"I#( @SBKN(KLLH MZ;2Z"$\[YVF?P_/,UMR&-CAM2N-23^$Z]T]/#Y/9 MD,SNA\^/0S*9CJX0NDY.USF';@23J6A$)B)DK^2!O97QX4HN.*W=-=-NO=9JO31O \MTB:[CF $Q%(E4B5 ML5V0N8%%0*0B(YF"0\&O,BR=Z@KUVS$&>939O7,@AV$(^5!?O!^03_ <>1+E M9+ADO>E^1_['WQU?F0T9;IE(V05I^Y H[B(I%3:^HF1X:,;'Q[?8R=+QX9+S ME,,,MOV&BQ$61!V,K:HF'%X./;'GP MSI3<N.?V*H17EQ<.KPD>TF=0&LM.?/#F]HG!%#[)3!V,KRHN'UX9L M"H?0_YY&P05^:6!ESBOJBH<7A$\R )_,-E)@A:Y"Q".=KDM:==)" [XH)QY> M!;XH;@P3X)LX3L4A:>M2,%RHJE7QBE+BX9E_+B,><,/%FCQ"A"M.HU(>7*6* MQR]*AX\G]YEBEP&XA\$2VW>4T-1![_NT6I5/885>)5E1+WP\N?^';*)U"F25 M@+AL)>#1'@'/S@MNH*N3*^+Y/RU_)G,6I!!OI63 MBPL:E:+S5N1ZOV(O83\=L)!,):Q223YK1LR&@>^,71$A@7D5FF=]Z7XG5 J+ MO^,4;.UH2V\_C\!.";RC2<16H.->M<$':O_%87]B9)+M\I?2&!EGAQM&8>': M!^#^2DKS?F(_'.3??0;_ %!+ P04 " #<@FU6GZ ;\+$" #B# #0 M 'AL+W-T>6QEO%DN7/ZZZ>S;"=I=67=A['-HN6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZF MTVY#;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,7 M8&F? KP(&K XU7=>&18/ MQA<0&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B< M45XH!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^, M%F)?A+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL> M]O[+"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PEY7>>9 ]IV03NA1.XJR MY/K%.?7A'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD\%G'!QR>(W?#$T%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/ MAG$##RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+ MV.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0 MIA@"IQ%', ; 4/2='@//GL?)=-[*CG_5U/\!%!+ P04 " #<@FU6EXJ[ M', 3 @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6 M!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV M)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(= MI7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( M -R";5:JQ"(6,P$ "(" / >&PO=V]R:V)O;VLN>&ULC5'1;L(P#/R5 M*A^P%K0A#5%>0-N0I@V-B??0NM0BB2O'A8VOG]NJ&M)>]I31=B;FJ19IZFL:C!VWA'#02=5,3>BD(^IK%AL&6L <2[=)IEL]1;#&:Y M&+6VG-X"$B@$*2C9$7N$2_R==S Y8\0#.I3OW/1W!R;Q&-#C% MB/%*0:S;%4S.Y68R#/; @L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\ M@RX/J!5Z0B? :ROPS-0V&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'! M=09#K+&))@G60VY6= ;N\N@#FW+()FKJIBF>HPYX4P[V1D\E5!B@?%.9J+SV M4VPYZ8Y>9WK_,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04 " #<@FU6)!Z; MHJT #X 0 &@ 'AL+U]R96QS+W=O[IFB MG#S^0W1UW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6 M<%H@XLD@;6E6?;!/3K3G>1,)KM\,<'AT_@%02P,$% @ W()M M5F60>9(9 0 SP, !, !;0V]N=&5N=%]4>7!E&ULK9--3L,P$(6O M$F5;)2XL6*"F&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1 ML.B=]=B4'5%\% )5!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3K MU3.T.EY&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY8 M4(JKA%SY'7#J>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F," MJ;$#(&?KT70Q32:>,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R M]>S[04Y;@[Z1S>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]> M?P%02P$"% ,4 " #<@FU6!T%-8H$ "Q $ @ $ M 9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0 ( -R";5;N.K"M[0 "L" M 1 " :\ !D;V-0&UL4$L! A0#% @ W()M5@!X0<^C! Q( !@ M ("!# @ 'AL+W=O4, !X;"]S='EL M97,N>&UL4$L! A0#% @ W()M5I>*NQS $P( L M ( !P0\ %]R96QS+RYR96QS4$L! A0#% @ W()M5JK$(A8S 0 (@( M \ ( !JA 'AL+W=O\2 !;0V]N=&5N=%]4>7!E&UL4$L%!@ ) - D /@( #D4 $! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://hookipapharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm239380d1_8k.htm hook-20230309.xsd hook-20230309_lab.xml hook-20230309_pre.xml tm239380d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm239380d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm239380d1_8k.htm" ] }, "labelLink": { "local": [ "hook-20230309_lab.xml" ] }, "presentationLink": { "local": [ "hook-20230309_pre.xml" ] }, "schema": { "local": [ "hook-20230309.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "hook", "nsuri": "http://hookipapharma.com/20230309", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm239380d1_8k.htm", "contextRef": "From2023-03-09to2023-03-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://hookipapharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm239380d1_8k.htm", "contextRef": "From2023-03-09to2023-03-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://hookipapharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001104659-23-031786-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-031786-xbrl.zip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end